Scientific area
3.1 Basic medicine
Discipline(s)
Neurosciences (including psychophysiology)
Project title
BIA 9 - 1067 (Opicapone)
Scientific Coordinator's name:
Prof. Patrício Soares-da-Silva
Scientific Coordinator's e-mail:
psoares.silva@bial.com
Principal R&D Unit:
Prof. Patrício Soares-da-Silva
Other R&D Units involved in the project:
Other R&D units involved in the project
Project keyword(s)
BIA 9-1067, Opicapone, Parkinson Disease, COMT, Levodopa
Short abstract and comments
Opicapone (BIA 9-1067) is currently under developed by BIAL (Portela & Cª, S.A.) to be used in combination with levodopa/carbidopa or levodopa/benserazide preparations in Parkinson’s disease (PD) patients. BIA 9-1067 is a selective and reversible catechol-O-methyltransferase (COMT) inhibitor that increases levodopa plasma levels when co-administered with levodopa and a peripheral dopa decarboxylase inhibitor (DDCI).
Potential uses/indications
Parkinson Disease
Status
Ongoing
Partner Status: Seeking Partners?
Yes
Grant number (QREN, FP7, Eureka, etc)
QREN 4584
Last edited on
2011-11-09 14:21:17